Short Description: Pennsieve is a platform that enables pharmaceutical companies to design smarter clinical trials by predicting which patients are most likely to respond to treatment. By analyzing their immune profiles, Pennsieve’s approach de-risks clinical trial designs and improves the probability of success.
Lessons Learned: Our primary objectives were initially faster patient recruitment, streamlined site operations, and improved use of immune profiling to find trial participants. Through customer discovery, we learned the real bottleneck is predictive biomarkers, not recruitment. We now focus on helping sponsors predict which patients will respond before launching expensive trials, increasing overall probability of trial success.
Names and Affiliation of Team members:
Leonardo Guercio, Director of Strategy & BD, University of Pennsylvania, Perelman School of Medicine, Colton Center for Autoimmunity
Daniel Shackleton, ELITE Entrepreneurial Fellow, University of Pennsylvania, The Wharton School, Penn Health-Tech